Physician profile
Christopher M Smith
NPI 1598729055
$6,346.59
in general payments reported to CMS, 2019-2025
43 companies · $37.88 in 2025
The $37.88 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,534 · 2020: $894 · 2021: $1,060 · 2022: $1,344 · 2023: $1,409 · 2024: $67.06 · 2025: $37.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $990.18 | 2019-2024 | Vraylar, Ubrelvy, Viberzi |
| Pfizer INC. | $730.20 | 2019-2025 | |
| Novo Nordisk INC | $521.99 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $467.36 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $376.14 | 2019-2023 | Farxiga, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $329.93 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $296.04 | 2019-2025 | Otezla, Repatha, Prolia |
| W. L. Gore & Associates, INC. | $274.89 | 2019 | |
| Merck Sharp & Dohme LLC | $250.90 | 2019-2023 | Belsomra |
| Amarin Pharma, INC. | $244.44 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.63 | 2019-2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $167.84 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $146.42 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.45 | 2019-2023 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $131.96 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.